Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 2
1973 1
1974 7
1975 6
1976 5
1977 3
1978 2
1979 2
1980 1
1981 2
1982 5
1983 1
1984 4
1985 8
1986 7
1987 2
1988 2
1989 13
1990 12
1991 12
1992 20
1993 24
1994 36
1995 29
1996 39
1997 60
1998 49
1999 75
2000 90
2001 96
2002 128
2003 152
2004 132
2005 150
2006 168
2007 180
2008 187
2009 193
2010 205
2011 255
2012 240
2013 253
2014 323
2015 339
2016 360
2017 335
2018 314
2019 306
2020 338
2021 314
2022 305
2023 281
2024 87

Text availability

Article attribute

Article type

Publication date

Search Results

5,629 results

Results by year

Filters applied: . Clear all
Page 1
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
Jabbour E, Kantarjian H. Jabbour E, et al. Am J Hematol. 2018 Mar;93(3):442-459. doi: 10.1002/ajh.25011. Am J Hematol. 2018. PMID: 29411417 Free article. Review.
DISEASE OVERVIEW: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. ...Frontline therapy: Four tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, dasatinib, and bosutinib are approved by the Unite …
DISEASE OVERVIEW: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 a …
Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
Hymes J, Bickimer T, Jackson JH, Bookhart BK, Mody SH, Tak Piech C. Hymes J, et al. Curr Med Res Opin. 2007 Aug;23(8):1931-7. doi: 10.1185/030079907X210705. Curr Med Res Opin. 2007. PMID: 17624232 Review.
OBJECTIVE: To compare real-world dosing patterns, drug costs, and hematologic outcome in anemic chronic kidney disease (CKD) patients, not receiving dialysis, who switched from darbepoetin alfa (DARB) to epoetin alfa (EPO) in a community practice setti …
OBJECTIVE: To compare real-world dosing patterns, drug costs, and hematologic outcome in anemic chronic kidney disea …
The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece.
Souliotis K, Kousoulakou H, Hillas G, Tzanakis N, Toumbis M, Vassilakopoulos T. Souliotis K, et al. Int J Chron Obstruct Pulmon Dis. 2017 May 10;12:1395-1400. doi: 10.2147/COPD.S132825. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28546747 Free PMC article.
The objective of this study was to explore the direct and indirect costs associated with COPD and identify the key cost drivers of disease management in Greece. ...In addition, absenteeism and caregiver's costs were recorded in order to quantify indirect COPD …
The objective of this study was to explore the direct and indirect costs associated with COPD and identify the key cost drivers of …
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS, Karagiannis PC, Peyerl FW. Joy MS, et al. J Manag Care Pharm. 2007 Jun;13(5):397-411. doi: 10.18553/jmcp.2007.13.5.397. J Manag Care Pharm. 2007. PMID: 17605511 Free PMC article. Review.
To refine subsequent searches, the authors added Boolean operators to the following secondary and tertiary search terms: parathyroid hormone, chronic kidney disease, renal osteodystrophy, adynamic bone disease, vascular calcification, cardiovascular diseas …
To refine subsequent searches, the authors added Boolean operators to the following secondary and tertiary search terms: parathyroid hormone …
The Effect of Medical Choice on Health Costs of Middle-Aged and Elderly Patients with Chronic Disease: Based on Principal-Agent Theory.
Li D, Su M, Guo X, Zhang W, Zhang T. Li D, et al. Int J Environ Res Public Health. 2022 Jun 21;19(13):7570. doi: 10.3390/ijerph19137570. Int J Environ Res Public Health. 2022. PMID: 35805231 Free PMC article.
(1) Background: The discussion on how to reduce the health costs of chronic disease patients has become an important public health issue. Limited research has been conducted on how chronic disease patients' medical choice of public and private m …
(1) Background: The discussion on how to reduce the health costs of chronic disease patients has become an important pu …
Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease.
Castaldi PJ, Rogers WH, Safran DG, Wilson IB. Castaldi PJ, et al. Chest. 2010 Sep;138(3):614-20. doi: 10.1378/chest.09-3031. Epub 2010 Apr 23. Chest. 2010. PMID: 20418367 Free PMC article.
BACKGROUND: Chronic pulmonary diseases (CPDs) such as asthma and COPD are associated with particularly high rates of cost-related medication nonadherence (CRN), but the degree to which inhaler costs contribute to this is not known. ...In multivariate models, the odd …
BACKGROUND: Chronic pulmonary diseases (CPDs) such as asthma and COPD are associated with particularly high rates of cost-related med …
Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema.
Wilson L, Devine EB, So K. Wilson L, et al. Respir Med. 2000 Mar;94(3):204-13. doi: 10.1053/rmed.1999.0720. Respir Med. 2000. PMID: 10783930 Free article.
In this study we aimed to estimate direct medical costs of Chronic Obstructive Pulmonary Disease (COPD) by disease type; chronic bronchitis and emphysema. ...Emphysema, which is more severe, has higher costs per prevalent case ($1341 vs. …
In this study we aimed to estimate direct medical costs of Chronic Obstructive Pulmonary Disease (COPD) by disease …
Chronic obstructive pulmonary disease involves substantial health-care service and social benefit costs.
Jensen MB, Fenger-Grøn M, Fonager K, Omland Ø, Vinding AL, Hansen JG. Jensen MB, et al. Dan Med J. 2013 Jan;60(1):A4557. Dan Med J. 2013. PMID: 23340185 Free article.
INTRODUCTION: The present study compared health care-related costs and the use of social benefits and transfer payments in participants with and without chronic obstructive pulmonary disease (COPD), and related the costs to the severity of the COPD. .. …
INTRODUCTION: The present study compared health care-related costs and the use of social benefits and transfer payments in participan …
The effect of doxofylline in asthma and COPD.
Cazzola M, Matera MG. Cazzola M, et al. Respir Med. 2020 Apr;164:105904. doi: 10.1016/j.rmed.2020.105904. Epub 2020 Feb 19. Respir Med. 2020. PMID: 32094104 Free article. Review.
In any case, its anti-inflammatory effects and capacity to reverse corticosteroid resistance deserve consideration, but it can induce numerous side effects and drug-drug interactions and frequently requires measurement of drug levels in plasma. ...
In any case, its anti-inflammatory effects and capacity to reverse corticosteroid resistance deserve consideration, but it can induce numero …
Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis.
Roggeri A, Roggeri DP, Zocchetti C, Bersani M, Conte F; ReNe (Renal Lombardy Network); Additional contributors from ReNe Network. Roggeri A, et al. J Nephrol. 2017 Apr;30(2):263-269. doi: 10.1007/s40620-016-0291-8. Epub 2016 May 10. J Nephrol. 2017. PMID: 27165160
BACKGROUND: Chronic kidney disease (CKD) progression is associated with significant comorbidities and costs. In Italy, limited evidence of healthcare resource consumption and costs is available. We therefore aimed to investigate the direct healthcare …
BACKGROUND: Chronic kidney disease (CKD) progression is associated with significant comorbidities and costs. In Italy, …
5,629 results